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Abstract 1 
Background: The risk of recurrent ischemic and bleeding events after primary percutaneous 2 
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may not 3 
be uniform over time, which may impact the benefit-risk ratio of guideline-recommended 4 
antithrombotic therapies in different intervals. 5 
Objectives: We sought to characterize the average daily ischemic rates (ADIR) and average 6 
daily bleeding rates (ADBR) within the first year after primary PCI for STEMI.  7 
Methods: Among 3,602 STEMI patients enrolled in the HORIZONS-AMI trial, all ischemic and 8 
bleeding events, including recurrent events, were classified according to the timing of their 9 
occurrence as acute (≤24 hours after PCI), subacute (day 1 to 30), and late (day 30 to 1 year). 10 
Patients were treated with aspirin and clopidogrel for the entire year. ADIR included cardiac 11 
death, reinfarction and definite stent thrombosis. ADBR included non-CABG-related TIMI 12 
major and minor bleeding. ADIR and ADBR were calculated as the total number of events 13 
divided by the number of patient-days of follow-up in each interval assuming a Poisson 14 
distribution. Generalized estimating equations were used to test the absolute least square mean 15 
differences (LSMD) between ADIR and ADBR. 16 
Results: The ADIR and ADBR both exponentially decreased from the acute to the late periods 17 
(p<0.0001). While there were no significant differences in ADIR and ADBR in the acute phase 18 
(LSMD: +0.11%; 95% CI: -0.35% to 0.58%; p=0.63), the ADBR was greater than the ADIR in 19 
the subacute phase (LSMD: -0.39%; 95% CI: -0.58% to -0.20%; p<0.0001). In the late phase, the 20 
ADIR exceeded the ADBR (LSMD: +1.51%; 95% CI: 1.04% to 1.98%; p<0.0001). 21 
Conclusions: After primary PCI, the ADIR and ADBR both markedly decreased over time. 22 
While the rates for bleeding exceeded those for ischemia within 30 days, the daily risk of 23 
4 
 
ischemia significantly exceeded the one of bleeding beyond 30 days, supporting the use of 1 
intensified platelet inhibition during the first year after STEMI. 2 
Key Words: STEMI; PCI; Average Daily Rate; Ischemic Events; Bleeding Events. 3 
 4 
  5 
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Condensed Abstract 1 
We characterized the average daily ischemic rate (ADIR) and average daily bleeding rate 2 
(ADBR) within the first year after primary PCI for STEMI. The ADIR and ADBR both 3 
exponentially decreased from the acute to the subacute to the late periods (p<0.0001). While the 4 
ADBR was greater than the ADIR in the first 30 days (least square mean difference [LSMD]: -5 
0.39%; 95% CI: -0.58% to -0.20%; p<0.0001), the ADIR significantly exceeded the ADBR 6 
beyond 30 days (LSMD: +1.51%; 95% CI: 1.04% to 1.98%; p<0.0001), supporting the use of 7 
intensified platelet inhibition during the first year after STEMI.  8 
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Abbreviation List 1 
ADR = Average daily rate 2 
 3 
ADIR = Average daily ischemic rate 4 
 5 
ADBR = Average daily bleeding rate 6 
 7 
GPI = Glycoprotein IIb/IIIa inhibitor 8 
 9 
MI = Myocardial infarction 10 
 11 
PCI = Percutaneous coronary intervention 12 
 13 
STEMI = ST-segment elevation myocardial infarction 14 
 15 
ST = Stent thrombosis 16 
 17 
UFH = Unfractionated heparin  18 
7 
 
Patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary 1 
percutaneous coronary intervention (PCI) are at high risk for ischemic and bleeding events, both 2 
of which strongly impact subsequent morbidity and mortality (1-4). The selection of optimal 3 
antithrombotic agents in the acute and chronic phases after STEMI, in terms of their potency and 4 
duration, requires a careful evaluation of the offsetting risks of ischemia and bleeding (5-7). 5 
While the predictors and impact of ischemic and hemorrhagic events after primary PCI in 6 
STEMI have been investigated (1,2), their absolute and relative rates over time remain uncertain. 7 
In this regard the risk for recurrent ischemic and bleeding events may not be uniform over time, a 8 
consideration which may influence the benefit-risk ratio of guideline recommended 9 
antithrombotic therapies. For example, since the highest rate of ischemic events occurs in the 10 
first few days or weeks after STEMI (8,9), a strategy of potent platelet inhibition might be 11 
considered during the first month after patient presentation, if the bleeding risk is not excessive 12 
in this period. Thereafter down-titrating to a less potent regimen might offer a favorable balance 13 
of ischemic protection vs. bleeding avoidance. Such considerations rely on understanding the 14 
relative risks of ischemia and bleeding in different risk periods. 15 
All adverse outcomes (including recurrent events) must be considered for the true burden 16 
of ischemic and bleeding complications to be fully appreciated. However, conventional time-to-17 
event analyses censor patients after the first endpoint event is experienced, thereby masking 18 
subsequent recurrent adverse events, reducing statistical power and diminishing appreciation for 19 
the potential benefit (or harm) of preventative therapies (10). We therefore determined the 20 
average daily rate (ADR) of all ischemic and bleeding events in the first year after primary PCI 21 
in patients enrolled in the Harmonizing Outcomes with RevascularIZatiON and Stents in Acute 22 
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Myocardial Infarction (HORIZONS-AMI) trial, to better characterize the total and temporal-1 
related burden of adverse outcomes after STEMI. 2 
 3 
METHODS 4 
Study Design and Objectives. The study design of the HORIZONS-AMI trial has been 5 
previously described (11,12). Briefly, HORIZONS-AMI was a multicenter, international, open-6 
label, 2 x 2 factorial randomized controlled trial that enrolled 3,602 patients presenting with 7 
STEMI within 12 hours from onset of symptoms. Eligible patients were randomized 1:1 to 8 
unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa inhibitor (GPI) versus bivalirudin. A 9 
total of 3,202 eligible patients were then randomized again in a 3:1 ratio to either implantation of 10 
a paclitaxel-eluting stent or a bare metal stent. Aspirin 324 mg chewed or 500 mg intravenously 11 
was given before PCI, and 75 to 81 mg po qd was prescribed indefinitely after discharge. A 12 
loading dose of clopidogrel (300 or 600 mg per investigator discretion) was administered pre-13 
PCI, followed by 75 mg po qd for at least 1 year. Clinical follow-up was performed at 30 days, 1 14 
year, 2 years and 3 years following the index procedure. The study was approved by an 15 
institutional review board and/or ethical committee at each center participating in the study. All 16 
enrolled patients provided informed written consent. 17 
The objectives of the present study were to (i) determine the average daily ischemic rate 18 
(ADIR) and average daily bleeding rate (ADBR) within different time intervals and overall 19 
within the first year following primary PCI for STEMI (the time period for which aspirin and 20 
clopidogrel were prescribed for all patients); (ii) to examine the extent to which recurrent events 21 
contribute to the total burden of adverse outcomes; and (iii) to determine whether randomized 22 
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intraprocedural antithrombotic treatment (bivalirudin monotherapy versus UFH plus GPI) 1 
affected these relative and absolute rates. 2 
 Endpoint and Time Interval Definitions. ADIR events were defined as cardiac death, 3 
myocardial infarction (MI) and definite stent thrombosis (ST). ADBR events were defined as 4 
Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding unrelated to coronary 5 
artery bypass graft surgery (CABG). The definition of MI in the peri-procedural and non-6 
procedural periods has been previously described (9,10). ST was defined according to the 7 
Academic Research Consortium criteria (13). Net adverse clinical events (NACE) were defined 8 
as death, MI, definite ST and TIMI major and minor bleeding. The ADR for ischemic and 9 
bleeding events were categorized according to the timing of their occurrence in the following 10 
time intervals: acute phase (≤24 hours), subacute phase (day 1 to day 30), early phase (0 to 30 11 
days), and late phase (day 30 to day 365). To account for the sometimes delayed recognition and 12 
diagnosis of bleeding events, ADRs were also examined using an alternative cut-off between the 13 
acute and the subacute phases, specifically: day 0 to day 3 (modified acute phase) and day 3 to 14 
day 30 (modified subacute phase). A clinical events committee blinded to treatment group 15 
allocation independently adjudicated all endpoint events through original source documents 16 
evaluation. 17 
Statistical Analyses. The events of death (all-cause, cardiac and non-cardiac), MI, 18 
definite ST, and TIMI major and minor bleeding unrelated to CABG were examined in all 3,602 19 
patients randomized to bivalirudin monotherapy versus UFH plus GPI.  For this analysis, all 20 
events per patient were tabulated, as opposed to only the first event per patient, as is typically 21 
reported in time-to-first-event analyses. For example, a single patient could have 1 ST, 2 MIs and 22 
2 bleeds during the follow-up period. However, these had to be discrete, unrelated events. For 23 
10 
 
example, if a ST directly resulted in an MI, this was coded as only as a single ischemic event in 1 
the composite ADIR endpoint. However, if an ischemic event led to a bleeding event (or vice-2 
versa), these were considered as two separate discrete events (i.e. a major bleed led to 3 
development of an MI, or a ST led to a PCI with subsequent periprocedural major bleeding). 4 
The ADR for a given interval was defined as the total number of events in that interval 5 
divided by the total number of patient-days of follow-up (number of patients multiplied by how 6 
many days each patient was at risk in that given period). Generalized estimating equations were 7 
used to test the least square mean differences (LSMD) between the acute, subacute and late time 8 
periods, with the patient as a repeated measure and assuming a Poisson distribution. The latter 9 
analysis compared the average rates per patient and produced the LSMD, 95% confidence 10 
intervals (CI) and p-values for the pairwise comparisons. Generalized estimating equations were 11 
also used to test the LSMD between the average rates for ischemia and bleeding within each 12 
specific interval. Because the definition of ABDR does not contain non-cardiac death, as a 13 
sensitivity analysis we also calculated the LSMD between ischemia and bleeding after exclusion 14 
of cardiac death from the composite AIDR endpoint (i.e. with AIDR comprised only of MI or 15 
definite ST). For descriptive purposes, instantaneous daily rates, calculated as the number of 16 
events on a given day divided by the number of patients at risk on that day (censoring only 17 
deaths and patients lost to follow-up), were also determined - i.e. if on day 15 after PCI, 4 MIs 18 
occurred out of 300 patients alive and at risk on that day, the instantaneous daily rate would be 19 
1.3% (4/300). All analyses were then repeated in the randomized groups to determine the impact 20 
of procedural antithrombotic treatment with bivalirudin vs. UFH plus GPI on the ADRs in 21 
different time intervals, according to the intention-to-treat principle All statistical tests were 2-22 
11 
 
sided. A P value below 0.05 was considered statistically significant for hypothesis testing. 1 
Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, North Carolina). 2 
 3 
RESULTS 4 
Among the 3,602 patients presenting with STEMI within 12 hours of symptom onset 5 
enrolled in HORIZONS-AMI, 279 discrete ischemic events (cardiac death, MI and definite ST) 6 
and 271 non-CABG-related TIMI major and minor bleeding events occurred within the first year 7 
following primary PCI for STEMI. Of these, 59/279 (21.1%) ischemic events and 43/271 8 
(15.9%) bleeding events were recurrent and unrelated (Table 1). Conversely, most ischemic and 9 
bleeding events were not temporally related (Table 2). Only 22 of the 279 ischemic events 10 
(7.9%) were followed by a bleeding event, all occurring within 30 days. Following the 271 11 
bleeding events, an ischemic event occurred in only 43 cases (15.9%), most 30/43 (69.8%) 12 
within 30 days.  13 
The proportion of ischemic and bleeding events occurring in the acute, subacute and late 14 
time intervals is illustrated in Figure 1. Most of the bleeding events (90.8%) occurred in the early 15 
phase. Conversely, only 59.5% of ischemic events occurred within 30 days, while 40.5% of 16 
ischemic events occurred between 30 days and 1 year. The absolute number of ischemic and 17 
bleeding events occurring each day over the 1-year follow-up period is shown in Supplemental 18 
Figure 1, demonstrating the rapid and exponential reduction in the ADR of both ischemic and 19 
bleeding events after PCI in STEMI. 20 
 Average Daily Ischemic and Bleeding Rates Within 1 Year. The ADIR and ADBR up 21 
to 30 days, after 30 days and within the entire first year are shown in Figure 2. The ADIR peaked 22 
in the first 24 hours, and the ADBR peaked between day 2 and 3 (Supplemental Table 1). The 23 
12 
 
ADIR and ADBR in the acute, subacute, early and late phases are shown in Figure 3, Table 3, 1 
Supplemental Table 2 (using the 3-day modified acute and subacute definitions) and in 2 
Supplemental Table 3 (examining the in-hospital and out-of-hospital periods). Highly significant 3 
reductions in both ADIR (Table 4 and Figure 3A) and ADBR (Table 4 and Figure 3B) were 4 
observed as the patients transitioned from the acute to the subacute to the late periods (p<0.0001 5 
for both ADIR and ADBR, across all time intervals). Results were consistent in the modified 6 
acute and subacute intervals (Supplemental Table 4). The daily rates for ischemic and bleeding 7 
events are shown in Supplemental Figure 2.  8 
 Differences Between Average Daily Ischemic and Bleeding Rates at 1 Year. LSMDs 9 
between ADIR and ADBR across time intervals are shown in the Central Illustration. ADBR 10 
significantly exceeded ADIR in the early phase (day 0 to 30 days; LSMD: -0.39%; 95% CI: -11 
0.58% to -0.20%; p<0.0001). Within the early phase, there was no significant difference between 12 
ADIR and ADBR in the acute (0 to 1 day) phase, whereas ADBR exceeded ADIR in the 13 
subacute (day 1 to 30) phase. Using the alternative 3-day cut-off (Supplemental Figure 3), 14 
ADBR exceeded ADIR in the acute (day 0 to 3) phase, with no significant differences between 15 
ADIR and ADBR in the subacute (day 3 to 30) phase. Finally, ADIR significantly exceeded 16 
ADBR in the late phase (30 days to 1 year; LSMD: 1.51%; 95% CI: 1.04% to 1.98%; p<0.0001). 17 
Results were consistent after excluding cardiac death from the composite ischemic endpoint 18 
(Supplemental Figure 4). 19 
 Average Daily Ischemic and Bleeding Rates According to the Antithrombotic 20 
Treatment. Differences in ADRs between bivalirudin-treated and UFH+GPI-treated patients are 21 
illustrated in Supplemental Table 5 (using a cut-off of ≤24 hours for the acute phase) and 22 
Supplemental Table 6 (using a cut-off of ≤3 days for the acute phase). At 30 days, bivalirudin 23 
13 
 
was associated with lower rates of bleeding and mortality, with no significant differences 1 
observed in ADIR. Conversely, there were no significant differences in ADIR and ADBR 2 
between the two groups beyond 30 days. LSMDs between ADIR and ADBR in the bivalirudin 3 
arm and the UFH + GPI arm are shown in Supplemental Figure 5 and Supplemental Figure 6, 4 
respectively. In patients treated with bivalirudin, there were no significant differences between 5 
ADIR and ADBR within the first 30 days, whereas in patients treated with UFH + GPI, the rates 6 
of ADBR exceeded the rates of ADIR in the early period. ADIR significantly exceeded ADBR in 7 
the late phase (30 days to 1 year) for both antithrombotic regimens.  8 
 9 
DISCUSSION 10 
The main findings from the present analysis, in which the absolute and relative daily and 11 
interval rates of ischemic and bleeding events were characterized in the first year after primary 12 
PCI in 3,602 STEMI patients maintained on a dual antiplatelet regimen of aspirin and 13 
clopidogrel, are as follows: (i) the ADRs for both ischemic and bleeding events, including 14 
recurrent events, were highest early after the procedure and then rapidly declined over time; (ii) 15 
in the early period (0-30 days), the absolute rates of bleeding exceeded those of ischemia, and 16 
were influenced by the type of intraprocedural anticoagulation; (iii) in the late period (30 days to 17 
1 year), the ADR of ischemic events exceeded that of bleeding; in this period the rates of 18 
ischemia and bleeding were unaffected by the procedural anticoagulation regimen. These novel 19 
findings elucidate the time-related differences in the offsetting rates of ischemia and bleeding 20 
after primary PCI, and have implications for the use of more potent P2Y12 inhibitors and other 21 
bleeding avoidance strategies during various intervals after mechanical reperfusion therapy in 22 
STEMI. 23 
14 
 
The current analysis from the HORIZONS-AMI trial extends the findings from prior 1 
studies in which the competing daily rates of ischemia and bleeding have been examined. 2 
Previously, Bhatt et al in a post-hoc analysis from the Clopidogrel for High Atherothrombotic 3 
Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial estimated the 4 
daily instantaneous hazard of ischemic and bleeding events at 3 years in stable patients on aspirin 5 
plus placebo or clopidogrel.(14) However, conventional time-to-event analyses (such as Kaplan-6 
Meier methods and Cox proportional hazard models) are limited by the fact that patients are 7 
censored after the occurrence of the first endpoint event. This approach does not allow 8 
evaluation of multiple or recurrent events over time, and therefore impedes full appreciation of 9 
the overall disease burden and effects of concomitant treatments (15). For example, in trials of 10 
heart failure therapies, as many as 50% of heart failure re-hospitalizations are recurrent events 11 
occurring in single participants (16,17). Application of time-to-first-event analysis for such 12 
endpoints results in a substantial loss of information and statistical power (18). In the present 13 
study, we examined the daily risk of discrete first time and recurrent ischemic and bleeding 14 
events over 1 year after primary PCI for STEMI. Approximately 21% of all ischemic events and 15 
16% of all bleeding events occurring within 1 year were recurrent events. Moreover, by detailed 16 
chart review we examined the inter-relationship of ischemic and bleeding events. For example, it 17 
might be envisioned that many major bleeds during follow-up arise from PCI treatment of 18 
ischemic complications (e.g. ST), or that many ischemic events arise after discontinuation of 19 
anti-platelet agents or other therapies to treat major bleeding. However, in contrast to this 20 
expectation, only a small proportion of adverse ischemic and bleeding events were temporally 21 
related to bleeding and ischemic events, respectively. These findings place into perspective the 22 
total burden of adverse events that occur within the first year after primary PCI for STEMI (in 23 
15 
 
patients treated with a dual antiplatelet regimen of aspirin and clopidogrel), and emphasize the 1 
relative independence of ischemic and bleeding complications in these high-risk patients. 2 
The absolute risk for ischemic events was highest early after the PCI procedure, and then 3 
exponentially decayed over time. This finding emphasizes that the early period (especially the 4 
first few days after primary PCI) is the interval in which more potent anti-platelet agents may 5 
have the greatest utility in improving prognosis. However, the absolute rate of bleeding was also 6 
greatest in this early period, and as such more potent agents may also produce harm in this 7 
interval. Such a trade-off is evidenced by procedural anticoagulation with bivalirudin rather than 8 
UFH + GPI, which in the first 24 hours results in greater rates of ST but less major bleeding. 9 
These offsetting risks can be favorably affected by routine use of a post-procedural bivalirudin 10 
infusion at 1.75 mg/kg/hr for 3-4 hours post-PCI, which may eliminate the excess acute risk of 11 
ST without increasing bleeding (19-21). Similarly, intensification of P2Y12 receptor inhibition 12 
with intravenous cangrelor compared to clopidogrel during the PCI procedure and for the first 2-13 
4 hours thereafter favorably reduces the acute and 48-hour rates of MI and ST without increasing 14 
major bleeding (22). In contrast, while use of prasugrel rather than clopidogrel in patients with 15 
acute coronary syndromes (ACS) was highly effective in reducing adverse ischemic events early 16 
after PCI, the excessive bleeding complications with this irreversible agent (including an 17 
increase in fatal and life-threatening bleeding) offset much of its benefits (23). Finally, given that 18 
in the first 30 days the overall burden of bleeding exceeded that of ischemia, bleeding avoidance 19 
strategies in this early high-risk period may be particularly effective in favorably shifting the 20 
benefit-risk equation. This finding possibly explains the early survival benefit seen in patients 21 
with STEMI undergoing primary PCI with radial artery compared to femoral artery access, and 22 
16 
 
with bivalirudin compared to UFH with or without GPI as intraprocedural antithrombotic therapy 1 
(24,25). 2 
In contrast to the first 30 days, ischemic and bleeding rates were substantially lower after 3 
30 days, and unaffected by the procedural anticoagulation regimen. However, in this period the 4 
absolute rate of ischemia was ~1.5% greater than the absolute rate of bleeding (representing a 5 
relative increase of ~50-fold) (Central Illustration), suggesting a particularly beneficial role in 6 
the late period for an agent able to further reduce ischemia (as long as major bleeding is not 7 
markedly increased). This finding may underlie the findings from the Study of Platelet Inhibition 8 
and Patient Outcomes (PLATO) trial, in which patients with STEMI and non-STEMI treated 9 
with aspirin plus ticagrelor rather than aspirin plus clopidogrel experienced a 1-year reduction in 10 
the rates of MI, ST, cardiac mortality and non-cardiac mortality, despite a modest increase in 11 
non-CABG-related major bleeding (26). Of note, the benefits of ticagrelor in this trial did not 12 
begin to emerge until several weeks after initiation, and continued to diverge throughout the 1-13 
year follow-up period, as predicted from the present study (26). Thus, the current analysis 14 
confirms current guidelines supporting consistent and high-intensity platelet inhibition to at least 15 
1 year after primary PCI in STEMI, emphasizing the selection of agents and consideration of 16 
patient co-morbidities to ensure an optimal balance of ischemia suppression and bleeding risk 17 
(27). 18 
The insights from the present study may also have bearing on the design of future 19 
randomized controlled trials for primary or secondary prevention in patients with ACS and in 20 
those undergoing PCI. In particular, inclusion of recurrent events (i.e. reinfarction or re-21 
hospitalization for cardiac causes) as a pre-specified primary outcome measure may increase the 22 
number of endpoint events facilitating studies of smaller sample size (impacting trial feasibility) 23 
17 
 
or with greater power (10). Such an approach may also allow for a more accurate estimation of 1 
the impact of a given intervention on overall disease burden. However, the present study also 2 
underscores the time dependence of the absolute and relative risks of off-setting events in disease 3 
states, as well as the potential risks vs. benefits of applying different therapeutic approaches in 4 
different periods. A treatment that offers a favorable benefit-risk profile early after patient 5 
presentation may not provide net clinical benefit later on (or vice versa).   6 
Limitations. The implications of our study findings should be assessed considering its 7 
strengths, limitations and unknowns. This analysis was performed from a large, prospective, 8 
international, multicenter randomized controlled trial with complete monitoring and event 9 
adjudication, therefore providing robust findings. Only first-generation drug-eluting stents and 10 
bare metal stents were used, and we did not study an UFH only arm, which some centers employ 11 
in primary PCI. In addition, more than 90% of patients were treated via femoral access, which 12 
has been associated with greater risk of bleeding and vascular complications than transradial 13 
access (24,25). However, in contemporary US practice, femoral access and UFH+GPI are still 14 
used in up to 90% and 40% of STEMI cases, respectively (28). Novel and more potent P2Y12-15 
receptor inhibitors (ticagrelor, prasugrel and cangrelor) were not available during study 16 
enrollment, and therefore our findings apply to an aspirin and clopidogrel-treated population. 17 
These newer treatments may affect the absolute and relative risks of ischemia vs. bleeding, 18 
although the general concepts still apply. Moreover, clopidogrel is still prescribed at hospital 19 
discharge in up to 60-70% of patients with acute coronary syndromes in the United States (29-20 
31). The net effects of new strategies capable of suppressing ischemia but which may also 21 
increase bleeding depend on: 1) the absolute rates of these competing risks; 2) the relative 22 
reduction in ischemia vs. increase in bleeding with the new therapy; and 3) the relative impact of 23 
18 
 
ischemia vs. bleeding on overall patient outcomes, for example as measured by their effect on 1 
mortality, a factor not considered in the present report but previously investigated in both acute 2 
(32) and more chronic settings (33). In this regard, in the HORIZONS-AMI trial, non-CABG-3 
related protocol-defined bleeding was at least as strongly associated with all-cause mortality 4 
through 3-year follow-up as was reinfarction (adjusted HR 3.44 vs 2.88 respectively) (33). The 5 
observed peak for the rate of bleeding between day 2 and 3 may be related to ascertainment bias 6 
due to the typical nadir in hemoglobin that occurs after a periprocedural hemorrhagic event. For 7 
this reason we presented a sensitivity analysis with acute events defined as those occurring 8 
within 3 days. Finally, in the current analysis we estimated ADRs in the overall trial population. 9 
Since the absolute rates of ischemia and bleeding may vary with individual patient risk factors, 10 
further analyses are warranted to identify subgroups at relatively higher or lower risk for 11 
recurrent ischemic vs. bleeding events who may differentially benefit from more intensive anti-12 
ischemic therapies or bleeding avoidance approaches, respectively. 13 
Conclusions. In the HORIZONS-AMI trial, in patients with STEMI treated with primary 14 
PCI on a background of aspirin and clopidogrel for 1 year, the daily risk for both adverse 15 
ischemic and bleeding events was highest early after the procedure and then dramatically 16 
declined over time. However, in contrast to the early period, beyond 30 days the absolute risk for 17 
ischemia exceeded the risk for bleeding. The current findings support the use of potent platelet 18 
inhibition continuing through at least 1 year to prevent both primary and recurrent ischemic 19 
events, especially in patients without excessive bleeding risk. Implementation of bleeding 20 
avoidance strategies is also essential, especially in the acute and subacute phases after primary 21 
PCI. Finally, a substantial proportion of both ischemic and bleeding events that occurred during 22 
the 1 year follow-up period were discrete, recurrent events, although in most cases not related to 23 
19 
 
each other – these considerations should be taken into account when evaluating the effect of 1 
pharmacotherapies for secondary prevention after STEMI. 2 
 3 
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PERSPECTIVES 1 
Competency in Medical Knowledge: After primary PCI for STEMI the risk of first and 2 
recurrent ischemic and bleeding events is highest early after the procedure to then drastically 3 
decline over time. While the rates for bleeding exceeded those for ischemic events within 30 4 
days, the risk for ischemia significantly exceeded the risk for bleeding beyond 30 days. 5 
 6 
Competency in Patient Care: The present analysis supports the use of intensified platelet 7 
inhibition from clinical presentation throughout the first year after STEMI. Physicians should 8 
take into account the time-dependent and off-setting risk of recurrent ischemic and bleeding 9 
events when tailoring duration and potency of antiplatelet therapies.  10 
 11 
Translational Outlook: Future randomized controlled trials in the field of acute coronary 12 
syndromes should be designed to evaluate the overall burden of events by considering recurrent 13 
adverse events, which are censored in conventional time-to-event analyses. 14 
 15 
  16 
24 
 
Figure Legends 1 
Figure 1. Adverse event proportions during the first year after primary PCI for STEMI. 2 
Panel A: Proportion of adverse events occurring in the acute (≤24 hours), subacute (day 1 to day 3 
30), and late (day 30 to day 365) periods; Panel B: Proportion of adverse events occurring in the 4 
early (day 0 to day 30) and late (day 30 to day 365) periods. ADIR = Average Daily Ischemic 5 
Rate; ADBR = Average Daily Bleeding Rate; NACE = Net Adverse Clinical Events. 6 
 7 
Figure 2. Average daily ischemic and bleeding rates within 1 year after primary PCI for 8 
STEMI. Panel A: From day 0 to day 365; Panel B: From day 0 to day 30. Panel C: From day 30 9 
to day 365. ADIR = Average Daily Ischemic Rate; ADBR = Average Daily Bleeding Rate; PCI: 10 
Percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction. 11 
 12 
Figure 3. Reductions in average daily ischemic and bleeding rates from the acute to the 13 
subacute to the late periods after primary PCI for STEMI. Panel A: Ischemic rate; Panel B: 14 
Bleeding rate. LSMD: Least Square Mean Differences. 15 
 16 
Central Illustration. Temporal differences in ischemic and bleeding rates after primary 17 
PCI for STEMI. Least square mean differences (LSMD) between the average daily ischemic 18 
and bleeding rates in the acute, subacute, early and late periods. The x-axis displays time. The y-19 
axis displays the LSMD between ischemia and bleeding, with LSMD >1 if ischemia exceeds 20 
bleeding and LSMD <1 if bleeding exceeds ischemia. In the early period (before 30 days), the 21 
rates of bleeding exceed those for ischemia. In the late period (from 30 days to 1 year), ADIR 22 
25 
 
significantly exceeds ADBR. ADBR: Average Daily Bleeding Rate; ADIR: Average Daily 1 
Ischemic Rate; CI: confidence interval; LSMD: least square mean differences.2 
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Table 1. Number of patients with discrete events within each time period and during the total 1-year study period  
 Endpoint 
Acute 
(day 0 to day 
1) 
Subacute 
(day 1 to day 
30) 
Late 
(day 30 to day 
365) 
Overall                        
(day 0 to day 365) 
Cardiac death, reinfarction or 
definite stent thrombosis 
    
Total events 37 129 113 279 
Patients with 1 event 37 106 83 220 
Patients with 2 events - 10 10 21 
Patients with 3 events - 1 2 3 
Patients with 4 events - - 1 2 
Death     
Total events 20 73 54 147 
Patients with 1 event 20 73 54 147 
Non-cardiac death     
Total events 1 8 33 42 
Patients with 1 event 1 8 33 42 
Cardiac death     
Total events 19 65 21 105 
Patients with 1 event 19 65 21 105 
Reinfarction     
Total events 14 58 85 157 
Patients with 1 event 14 47 70 127 
Patients with 2 events - 4 4 7 
Patients with 3 events - 1 1 4 
Patients with 4 events - - 1 1 
Definite stent thrombosis     
Total events 21 47 32 100 
Patients with 1 event 21 37 26 82 
Patients with 2 events - 5 3 6 
Patients with 3 events - - - 2 
TIMI major and minor     
27 
 
bleeding 
Total events 33 213 25 271 
Patients with 1 event 33 197 22 228 
Patients with 2 events - 5 - 17 
Patients with 3 events - 2 1 3 
TIMI: Thrombolysis In Myocardial Infarction. 
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Table 2. Relationships between ischemic and bleeding events 
Primary event Secondary event 0 to 7 days 7 to 30 days 0 to 30 days 30 days to 1 year 0 to 1 year 
Bleeding (N=271) Ischemia (N=43) 20/271 (7.4%) 10/271 (3.7%) 30/271 (11.1%) 13/271 (4.8%) 43/271 (15.9%) 
  - MI or ST (N=18) 5/271 (1.8%) 4/271 (1.5%) 9/271 (3.3%) 9/271 (3.3%) 18/271 (6.6%) 
  - Cardiac death (N=25) 15/271 (4.8%) 6/271 (2.2%) 21/271 (7.0%) 4/271 (1.5%) 25/271 (9.2%) 
Ischemia (N=279) Bleeding (N=22) 13/279 (4.7%) 9/279 (3.2%) 22/279 (7.9%) 0/279 (0.0%) 22/279 (7.9%) 
Results represent number of recurrent events / number of primary bleeding or ischemic events (%). Proportion of ischemic and bleeding 
events occurring within 365 days following a bleeding (upper panel) or ischemic event (lower panel), respectively. MI: Myocardial infarction; 
ST: Stent thrombosis. 
 
  
29 
 
Table 3. Average daily rates for adverse events in the acute, subacute, early and late periods 
Endpoint 
Acute 
(≤24 hours) 
Subacute 
(day 1 to day 30) 
Early 
(day 0 to day 30) 
Late 
(day 31 to day 365) 
Average daily ischemic rate* 37/3602 (1.0272%) 129/105435 (0.1224%) 166/109037 (0.1522%) 113/1116866 (0.0101%) 
Cardiac death 19/3602 (0.5275%) 65/105435 (0.0616%) 84/109037 (0.0770%) 21/1116866 (0.0019%) 
Reinfarction 14/3602 (0.3887%) 58/105435 (0.0550%) 72/109037 (0.0660%) 85/1116866 (0.0076%) 
Definite stent thrombosis 21/3602 (0.5830%) 47/105435 (0.0446%) 68/109037 (0.0624%) 32/1116866 (0.0029%) 
Average daily bleeding rate† 33/3602 (0.9162%) 213/105435 (0.2020%) 246/109037 (0.2256%) 25/1116866 (0.0022%) 
Average daily mortality rate 20/3602 (0.5552%) 73/105435 (0.0692%) 93 /109037 (0.0853%) 54/1116866 (0.0048%) 
Non-cardiac death 1/3602 (0.0278%) 8/105435 (0.0076%) 9/109037 (0.0083%) 33/1116866 (0.0030%) 
Average daily net adverse 
clinical events rate‡ 
70/3602 (1.9434%) 342/105435 (0.3244%) 412/109037 (0.3779%) 138/1116866 (0.0124%) 
Data reported as number of events/patient-day of follow-up (average daily rate) in each time-period. *Defined as cardiac death, reinfarction 
and definite stent thrombosis. †Defined as non-CABG-related TIMI major and minor bleeding. ‡Defined as any death, reinfarction, 
definite stent thrombosis, and non-CABG-related TIMI major and minor bleeding. 
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Table 4. Differences in average daily rates for adverse events in the acute, subacute, early and late periods. 
 Acute vs. Subacute Period  Acute vs. Late Period  
 Difference 95% CI P-value  Difference 95% CI P-value  
Average daily ischemic rate 2.13% 1.75 - 2.50 <0.0001  4.62% 4.24 - 5.00 <0.0001  
     Cardiac death 2.15% 1.64 - 2.66 <0.0001  5.64% 5.02-6.26 <0.0001  
     Reinfarction 1.96% 1.36 - 2.55 <0.0001  3.93% 3.37-4.50 <0.0001  
     Definite stent thrombosis 2.57% 2.04 - 3.10 <0.0001  5.32% 4.77-5.87 <0.0001  
Average daily bleeding rate 1.51% 1.15 - 1.87 <0.0001  6.01% 5.48 - 6.55 <0.0001  
Average daily mortality rate 2.08% 1.59 - 2.58 <0.0001  4.74% 4.23 - 5.26 <0.0001  
     Non-cardiac death 1.30% -0.78 - 3.38 0.22  2.24% 0.25 - 4.23 0.03  
Average daily net adverse clinical 
events rate 
1.79% 1.54 - 2.04 <0.0001  5.06% 4.76 - 5.35 <0.0001  
 Subacute vs. Late Period  Early vs. Late Period  
 Difference 95% CI P-value  Difference 95% CI P-value  
Average daily ischemic rate 2.49% 2.21 - 2.78 <0.0001  2.71 2.44 - 2.98 <0.0001  
     Cardiac death 3.49% 3.00 - 3.98 <0.0001  3.71 3.23 - 4.19 <0.0001  
     Reinfarction 1.98% 1.61 - 2.35 <0.0001  2.16 1.82 - 2.50 <0.0001  
     Definite stent thrombosis 2.74% 2.26 - 3.23 <0.0001  3.08 2.64 - 3.52 <0.0001  
Average daily bleeding rate 4.50% 4.05 - 4.95 <0.0001  4.62 4.18 - 5.07 <0.0001  
Average daily mortality rate 2.66% 2.31 - 3.01 <0.0001  2.87 2.53 - 3.21 <0.0001  
     Non-cardiac death 0.94% 0.17 - 1.72 0.02  1.03 0.29 - 1.76 0.006  
31 
 
Average daily net adverse clinical 
events rate 
3.27% 3.04 - 3.50 <0.0001  3.42 3.20 - 3.64 <0.0001  
Least square mean differences, confidence intervals and p-values for pairwise comparisons between the patient-
day event rates across the acute (day 0 to day 1), subacute (day 1 to day 30) and late (day 30 to day 365) periods. 
Generalized estimating equations were used to test the rate for differences between the three time periods with 
the patient as a repeated measure and assuming a Poisson distribution. Differences in reinfarction are not 
estimable due to absence of events in the acute phase. CI: confidence interval. 
 
